These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 37214204)

  • 1. Targeting Cancer Metabolism to Improve Outcomes with Immune Checkpoint Inhibitors.
    Fatima Z; Abonofal A; Stephen B
    J Immunother Precis Oncol; 2023 May; 6(2):91-102. PubMed ID: 37214204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Metabolism to Control Immune Responses in Cancer and Improve Checkpoint Blockade Immunotherapy.
    Luby A; Alves-Guerra MC
    Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Glucose or Glutamine Metabolic Therapy Combined With PD-1/PD-L1 Checkpoint Blockade Immunotherapy for the Treatment of Tumors - Mechanisms and Strategies.
    Ma G; Li C; Zhang Z; Liang Y; Liang Z; Chen Y; Wang L; Li D; Zeng M; Shan W; Niu H
    Front Oncol; 2021; 11():697894. PubMed ID: 34327138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immuno-Metabolism: The Role of Cancer Niche in Immune Checkpoint Inhibitor Resistance.
    Weng CY; Kao CX; Chang TS; Huang YH
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33514004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel strategy to fuel cancer immunotherapy: targeting glucose metabolism to remodel the tumor microenvironment.
    Liu X; Zhao Y; Wu X; Liu Z; Liu X
    Front Oncol; 2022; 12():931104. PubMed ID: 35924168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy.
    Kim J; Hong J; Lee J; Fakhraei Lahiji S; Kim YH
    J Control Release; 2021 Apr; 332():109-126. PubMed ID: 33571549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunometabolism and Its Potential to Improve the Current Limitations of Immunotherapy.
    Sheppard AD; Lysaght J
    Methods Mol Biol; 2020; 2184():233-263. PubMed ID: 32808230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the Tumor Microenvironment for Improving Therapeutic Effectiveness in Cancer Immunotherapy: Focusing on Immune Checkpoint Inhibitors and Combination Therapies.
    Chyuan IT; Chu CL; Hsu PN
    Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33801815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of immune cell metabolism by cancer cell oncogenic mutations.
    Madi A; Cui G
    Int J Cancer; 2020 Jul; 147(2):307-316. PubMed ID: 31994718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review to Understand the Crosstalk between Immunotherapy and Tumor Metabolism.
    Pandey P; Khan F; Upadhyay TK; Maqsood R
    Molecules; 2023 Jan; 28(2):. PubMed ID: 36677919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Turning enemies into allies-reprogramming tumor-associated macrophages for cancer therapy.
    Molgora M; Colonna M
    Med; 2021 Jun; 2(6):666-681. PubMed ID: 34189494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic Reprogramming in the Tumor Microenvironment With Immunocytes and Immune Checkpoints.
    Xu Y; He L; Fu Q; Hu J
    Front Oncol; 2021; 11():759015. PubMed ID: 34858835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy.
    Bader JE; Voss K; Rathmell JC
    Mol Cell; 2020 Jun; 78(6):1019-1033. PubMed ID: 32559423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current Clinical Applications and Future Perspectives of Immune Checkpoint Inhibitors in Non-Hodgkin Lymphoma.
    Apostolidis J; Sayyed A; Darweesh M; Kaloyannidis P; Al Hashmi H
    J Immunol Res; 2020; 2020():9350272. PubMed ID: 33178841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The roles of metabolic profiles and intracellular signaling pathways of tumor microenvironment cells in angiogenesis of solid tumors.
    Zalpoor H; Aziziyan F; Liaghat M; Bakhtiyari M; Akbari A; Nabi-Afjadi M; Forghaniesfidvajani R; Rezaei N
    Cell Commun Signal; 2022 Nov; 20(1):186. PubMed ID: 36419156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Emergence of Immune-checkpoint Inhibitors in Colorectal Cancer Therapy.
    Ghidini M; Fusco N; Salati M; Khakoo S; Tomasello G; Petrelli F; Trapani D; Petrillo A
    Curr Drug Targets; 2021; 22(9):1021-1033. PubMed ID: 33563194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
    Hargadon KM; Johnson CE; Williams CJ
    Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic modulation of immune checkpoints and novel therapeutic strategies in cancer.
    Wang Y; Wang Y; Ren Y; Zhang Q; Yi P; Cheng C
    Semin Cancer Biol; 2022 Nov; 86(Pt 3):542-565. PubMed ID: 35151845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic Hallmarks of Tumor and Immune Cells in the Tumor Microenvironment.
    Renner K; Singer K; Koehl GE; Geissler EK; Peter K; Siska PJ; Kreutz M
    Front Immunol; 2017; 8():248. PubMed ID: 28337200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.